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ABSTRACT
Introduction :  Numerous randomized 
clinical trials have demonstrated the efficacy 
and tolerability of aliskiren and aliskiren 
hydrochlorothiazide (aliskiren HCT) single-
pill combination therapy in patients with 
hypertension. The objective of the present 
study was to evaluate the effectiveness and 
safety of aliskiren-based therapy under daily life 
conditions in a multiethnic population. 
Methods: This observational, multicenter, 
noninterventional study, conducted at 
420 centers in Asia and the Middle East, 
included adult patients with hypertension who 
received treatment with aliskiren or aliskiren 
HCT as single or add-on therapy for a planned 
treatment period of at least 26 weeks. The 
main effectiveness assessments included the 
proportion of patients achieving therapeutic 
blood pressure (BP) goal (defined as systolic 
BP [SBP]/diastolic BP [DBP] <140/90 mmHg, or 
<130/80 mmHg in patients with diabetes) and 
BP response, and change in mean sitting BP 
from baseline to study end.
Results: Of 4,826 patients (mean age 51.4 years, 
65.9% male, 64.5% Asian, 41.5% diabetic) 
included in the study, 3,473 received aliskiren 
and 1,353 received aliskiren HCT. Almost half the 
study population (48.1%) received aliskiren or 
aliskiren HCT as add-on therapy. The therapeutic 
BP goal was achieved in 49.5% of patients 
treated with aliskiren and 48.3% of patients 
Enhanced content for Advances in Therapy 
articles is available on the journal web site: 
www.advancesintherapy.com 
S. R. Maddury ()
CARE Hospital, D.No.8-2-330/A/2, Banjara Hills, 




Al Zahra Hospital, Sharjah, UAE
K. M. H. S. S. Haque
Anwer Khan Modern Medical College, Dhanmondi, 
Dhaka
A. Echtay
Hariri University Hospital, Beirut, Lebanon
L. Go
Saint Luke’s Medical Center, Quezon City, Philippines
T. Gulzar
Hameed Latif Hospital, Lahore and the National 
Hospital Lahore, Pakistan 
M. Kadwa · S. Hristoskova
Novartis Pharma AG, Basel, Switzerland 
Adv Ther (2013)  30(2):176–89. 177
receiving aliskiren HCT; attainment of BP goal 
increased to more than 70% when a classic BP 
target of <140/90 mmHg was applied for all 
patients. Reductions in mean sitting SBP/DBP 
were significantly lower versus baseline for both 
aliskiren (24.1/12.2 mmHg) and aliskiren HCT 
(27.6/14.1 mmHg) and BP response rates were 
consistently achieved in more than 80% of all 
patients during the study. Aliskiren treatment 
was well tolerated with only a small proportion 
of patients experiencing adverse events (AEs; 
2.1%) and serious AEs (0.3%).
Conclusion: In this real-world, naturalistic 
setting, antihypertensive treatment with an 
aliskiren-based regimen was effective and well-
tolerated in this multiethnic population with 
arterial hypertension.
Keywords: Aliskiren; Aliskiren HCT; Asia; Direct 
renin inhibitor; Effectiveness; Hypertension; 
Middle East; Observational; Real-world; 
Tolerability
INTRODUCTION
As the number one cause of mortality 
worldwide [1], there is no doubt that 
hypertension is a major public health concern 
in today’s society. Current statistics report 
that globally almost 1 billion individuals 
have high blood pressure (BP) [2, 3], and 
by 2025, the prevalence of hypertension 
is expected to increase by about 60% to 
1.56 billion [2]. Importantly, almost three-
quarters of this hypertensive population will 
reside in economically developing countries [2]. 
Hypertension is one of the most common 
and treatable risk factors for cardiovascular 
(CV) morbidity and mortality [3]. It is also 
often clustered with other CV risk factors such 
as diabetes, obesity, and metabolic syndrome, 
placing patients at even greater risk of CV 
disease [4, 5]. Data from 2001 showed that 
nonoptimal BP, defined as systolic BP (SBP) 
≥115 mmHg, was responsible for 54% of all 
strokes and 47% of all cases of ischemic heart 
disease [6]. Moreover, approximately 80% of the 
CV disease burden attributable to hypertension 
occurred in low- and middle-income countries, 
including Asia and the Middle East [6].
Despite evidence showing that effective BP 
lowering can reduce the risk of CV events [7], 
and the availability of numerous efficacious 
antihypertensive agents, control of high BP 
to guideline-recommended targets remains 
a global challenge [8, 9]. Indeed, in parts of 
Asia, BP control rates in patients receiving 
antihypertensive treatment are as low as 
20% [10], a reflection of what is being seen 
elsewhere in the world. There are numerous 
reasons for failure to achieve BP targets in 
patients receiving antihypertensive treatment, 
including noncompliance/nonpersistence with 
therapy, suboptimal antihypertensive treatment 
efficacy, and poorly tolerated regimens [11].
Aliskiren is a first-in-class direct renin 
inhibitor, which acts at the rate-limiting 
step of the renin-angiotensin-aldosterone 
system (RAAS) and reduces plasma renin 
activity, angiotensin I, angiotensin II, and 
aldosterone [12, 13]. Numerous randomized, 
controlled clinical trials have demonstrated 
the efficacy and tolerability of aliskiren and the 
combination of aliskiren hydrochlorothiazide 
(aliskiren HCT) across a range of hypertensive 
patient populations, including those deemed 
difficult to treat, such as patients with stage 2 
hypertension [14], metabolic comorbidities, or 
obesity [15, 16], and the elderly [17]. 
As only limited published data are available 
on the real-world effectiveness and safety of 
aliskiren [18–20], particularly in regions such 
as Asia and the Middle East, the present study 
was conducted to characterize and assess the 
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effectiveness, safety and tolerability of aliskiren 
and the single-pill combination (SPC) of aliskiren 
HCT as antihypertensive therapy under daily-
life conditions during a planned observation 
and treatment period of at least 26 weeks in a 
multiethnic population.
MATERIALS AND METHODS
Study Design and Patient Population
This was an observational, multicenter, 
prospective, open-label, single-arm study 
conducted at 420 centers in Asia (Bangladesh, 
India, the Philippines, and Pakistan) and the 
Middle East (Bahrain, Kuwait, Lebanon, Oman, 
Qatar, and the United Arab Emirates) between 
June 2010 and August 2011. The study was 
conducted as a noninterventional trial and 
as such, therapy was prescribed in terms of 
the marketing authorization in the respective 
countries; the assignment of the patient to 
therapy was as per usual practice and clinically 
indicated, and was clearly separated from the 
decision to include the patient in the study. No 
additional diagnostic or monitoring procedures 
other than those usually performed as part 
of routine patient care were applied to the 
patients. The study protocol recommended that 
BP measurements were made in accordance 
with the 1988 American Heart Association 
Committee Report on BP determination [21]; 
however, this was an observational study and 
recommendations were made for guidance 
purposes only. 
Male and female patients aged ≥18 years 
with an established diagnosis of hypertension 
for which treatment with aliskiren or aliskiren 
HCT SPC as single or add-on therapy had 
been prescribed by a treating physician were 
eligible for inclusion in the study. Patients 
with any contraindication (as stated in the 
local prescribing information for the respective 
participating country) to aliskiren or aliskiren 
HCT were excluded from participation. 
Informed written consent for the collection and 
use of data was obtained from all participants, 
and the study was performed in accordance 
with national requirements and regulations. 
In accordance with the observational nature 
of this study, patients were not required to 
consent to taking the medication of interest, as 
treatment was decided prior to study entry in 
line with usual clinical practice. Patients were 
discontinued from the study if they withdrew 
informed consent or were no longer taking the 
medication of interest.
During the observational period of 
26 ± 8 weeks, data from at least two routine 
patient visits were recorded: the baseline visit, 
during which inclusion and exclusion criteria 
were assessed and baseline data collected, and a 
final visit at the end of the study. Additionally, 
the treating physician could record data from a 
visit performed at approximately 13 weeks after 
initiation of the study. Data collected included 
patient demographics, patient characteristics, 
details of the antihypertensive therapies 
prescribed, including dose of aliskiren or 
aliskiren HCT, concomitant medications, vital 
signs and weight measurements, laboratory 
values (if conducted), adverse events (AEs), and 
a final investigator assessment of the therapy 
with regard to effectiveness, tolerability and 
compliance.
Outcomes Assessments
The main effectiveness criterion was the 
proportion of patients who achieved therapeutic 
goal, defined as a target SBP <140 mmHg and 
diastolic BP (DBP) <90 mmHg. For patients 
with comorbid diabetes, the respective SBP and 
DBP goals were <130 mmHg and <80 mmHg at 
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the end of the study. Additional effectiveness 
criteria included the absolute change from 
baseline to end of study in mean sitting SBP 
(msSBP) and mean sitting DBP (msDBP), and the 
proportion of patients achieving a BP response 
(SBP response defined as SBP <140 mmHg 
[<130 mmHg in patients with diabetes] or a 
reduction of ≥20 mmHg; DBP response defined 
as DBP <90 mmHg [<80 mmHg in patients with 
diabetes] or a reduction of ≥10 mmHg). Safety 
and tolerability were assessed by monitoring and 
recording all AEs, serious AEs (SAEs), laboratory 
safety evaluations (if performed), physical 
examinations, vital signs, and body weight. At 
final study visit, an additional assessment was 
performed relating to the effectiveness and 
tolerability of therapy with aliskiren or aliskiren 
HCT, as well as treatment compliance, as judged 
by the study investigator according to the 
following grading: “below average,” “average,” 
“good,” or “very good.”
Statistical Analyses
Data from all countries and sites were pooled. All 
effectiveness and safety analyses were performed 
on the full analysis set (FAS), consisting of 
patients who provided informed consent, were 
assigned a patient number, and entered the 
study. Demographics and baseline characteristics 
were summarized with standard descriptive 
statistics. The proportion of patients achieving 
the therapeutic goal and BP response were 
summarized by visit. If no BP measurements were 
available at week 26, the week 13 measurement 
was carried forward (last observation carried 
forward [LOCF]). Changes from baseline in 
SBP and DBP were summarized with standard 
descriptive statistics by visit and analyzed with 
a one-sided t-test examining the hypothesis of 
no decrease from baseline. The test results were 
accompanied by 95% two-sided confidence 
intervals (CIs) for the mean. An additional 
analysis was performed for therapeutic BP goal 
and BP response using a classic BP target for 
patients with hypertension, i.e., <140/90 mmHg 
for therapeutic goal, <140 mmHg (or a reduction 
in SBP of ≥20 mmHg) for SBP response; and 
<90 mmHg (or a reduction in DBP of ≥10 mmHg) 
for DBP response. Data analysis was performed 
by DATAMAP GmbH, Freiburg, Germany using 
SAS, version 9.1 (SAS Institute, Cary, NC, USA).
RESULTS
Patient Disposition
Of the 5,366 patients enrolled in the study, 
evaluable data were available for 4,829 patients, 
all of whom were included in the FAS. Of 
these, three patients were excluded from the 
analyses because antihypertensive treatment was 
unknown. In total, 3,473 patients were treated 
with aliskiren (150 mg, n = 2,183; 300 mg, 
n = 1,290), while 1,353 patients were treated 
with aliskiren HCT SPC (150/12.5 mg, n = 762; 
150/25 mg, n = 60; 300/12.5 mg, n = 452; 
300/25 mg, n = 79). Both aliskiren and aliskiren 
HCT were given as single or add-on therapy. The 
study was completed by 4,600 (95.3%) patients 
(n = 3,278 in the aliskiren treatment group and 
n = 1,322 in the aliskiren HCT group). The main 
reason for premature discontinuation from 
the study was loss to follow-up in 181 (3.8%) 
patients (Table 1).
All patients included in the study were from 
Asia (Bangladesh 5.7%; India 17.9%; Pakistan 
6.2%; and the Philippines 11.3%) or the Middle 
East (Lebanon 22.1%; United Arab Emirates 
23.6%; Oman 2.8%; Qatar 3.1%; Kuwait 4.6%; 
and Bahrain 2.7%). Patient demographics 
and baseline characteristics are outlined in 
Table 2. The mean age was 51.4 years and the 
majority of patients were male (65.9%) and 
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Table 1  Patient disposition
  Aliskiren Aliskiren HCT Total
  n = 3,473 n = 1,353 n = 4,826
  n (%) n (%) n (%)
Completed 3,278 (94.4) 1,322 (97.7) 4,600 (95.3)
Discontinued 194 (5.6) 30 (2.2) 224 (4.6)
Unknown 1 (0.0) 1 (0.1) 2 (0.0)
Primary reason for premature discontinuation
Adverse event(s) 14 (0.4) 1 (0.1) 15 (0.3)
Abnormal laboratory value(s) 4 (0.1) 0 (0.0) 4 (0.1)
Abnormal test procedure  0 (0.0) 0 (0.0) 0 (0.0)
Unsatisfactory therapeutic eect 6 (0.2) 0 (0.0) 6 (0.1)
No longer requiring medication of interest 3 (0.1) 0 (0.0) 3 (0.1)
Withdrew consent 4 (0.1) 0 (0.0) 4 (0.1)
Lost to follow-up 156 (4.5) 25 (1.9) 181 (3.8)
Administrative problems 2 (0.1) 0 (0.0) 2 (0.0)
Death 3 (0.1) 1 (0.1) 4 (0.1)
Protocol deviation 2 (0.1) 1 (0.1) 3 (0.1)
Unknown 0 (0.0) 2 (0.2) 2 (0.0)
Full analysis set
HCT hydrochlorothiazide
Table 2  Patient demographics and baseline clinical characteristics
Variable Aliskiren Aliskiren HCT Total
  (n = 3,473) (n = 1,353) (n = 4,826)
Age (years), mean ± SD 51.0 ± 11.56 52.6 ± 10.48 51.4 ± 11.29
Gender, n (%)
 Male 2,294 (66.1) 885 (65.4) 3,179 (65.9)
 Female 1,178 (33.9) 468 (34.6) 1,646 (34.1)
Race, n (%)
 Caucasian 754 (21.7) 412 (30.5) 1,166 (24.2)
 Black 64 (1.8) 29 (2.1) 93 (1.9)
 Asian 2,317 (66.7) 795 (58.8) 3,112 (64.5)
 Other 330 (9.6) 115 (8.5) 445 (9.2)
BMI ≥30 kg/m2, n (%) 1,014 (29.2) 466 (34.4) 1,480 (30.7)
Diabetes, n (%) 1,362 (39.2) 643 (47.5) 2,005 (41.5)
Prior essential hypertension, n (%) 3,422 (98.5) 1,343 (99.3) 4,765 (98.7)
Mean duration of hypertension, n (years) 1,631 (3.28) 626 (3.58) 2,257 (3.36)
Prior antihypertensive treatment, n (%)a 2,443 (70.3) 1,011 (74.7) 3,454 (71.6)
Baseline BP (mmHg), mean ± SD
 SBP 153.9 ± 15.01 157.1 ± 14.98 154.8 ± 15.07
 DBP 93.5 ± 8.94 95.0 ± 8.76 93.9 ± 8.92
Full analysis set
BMI body mass index, BP blood pressure, DBP diastolic blood pressure, HCT hydrochlorothiazide, SBP systolic blood 
pressure, SD standard deviation
a Most frequently used agents prior to the start of the study included angiotensin receptor blockers (26.7%), beta-blockers 
(26.5%) and calcium channel blockers (26.4%)
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Asian (64.5%). Furthermore, the mean duration 
of hypertension was 3.4 years. Of note, 41.5% 
of patients had concomitant diabetes and more 
than 30% were classified as being obese (body 
mass index [BMI] ≥30 kg/m2). Prior to the start 
of the study, more than 70% of patients had 
been treated with antihypertensive medications 
(predominantly angiotensin II receptor blockers 
[ARBs], beta-blockers, calcium channel blockers 
[CCBs], and angiotensin converting enzyme 
inhibitors [ACEIs]), receiving on average 1.1 
antihypertensive medications. In almost half of 
the patients (n = 2,323; 48.1%), aliskiren (n = 
1,685; 48.5%) or aliskiren HCT (n = 638; 47.2%) 
was prescribed as add-on therapy, with an 
average of 0.7 different types of antihypertensive 
medications prescribed per patient in addition 
to the medication of interest. The most common 
types of antihypertensive medications used in 
combination with aliskiren or aliskiren HCT 
were beta-blockers (20.6%), CCBs (19.2%), ARBs 
(15.5%), and ACEIs (6.9%).
Treatment Effectiveness
The proportion of patients who reached the 
defined therapeutic BP goal (SBP <140 mmHg and 
DBP <90 mmHg [SBP <130 and DBP <80 mmHg, 
respectively, in patients with diabetes]) at 
week 26 (LOCF) was 49.2% overall, 49.5% for 
aliskiren and 48.3% for aliskiren HCT (Table 3). 
When analyzed according to diabetic status, few 
patients with diabetes (n = 320; 16.3%) achieved 
a BP goal of <130/80 mmHg; by contrast, 73.1% 
(n = 1,977) of nondiabetic patients achieved 
a therapeutic goal of <140/90 mmHg. In the 
additional retrospective analysis, whereby 
therapeutic goal and BP response criteria were 
revised with a “classic” BP target of <140 mmHg 
and <90 mmHg and applied to all patients, the 
proportion of patients achieving the therapeutic 
goal increased to more than 70% at week 26 
(LOCF; Table 3). Furthermore, no difference was 
seen with regard to achievement of therapeutic 
BP goal between patients with diabetes (73.8%) 
and the total population (73.4%).
Both aliskiren and aliskiren HCT were 
associated with high BP response rates. At 
week 26 (LOCF), the proportion of aliskiren-
treated patients achieving the predefined 
response for SBP and DBP was 83.6% and 
84.4%, respectively; the corresponding BP 
response rates in patients receiving aliskiren 
HCT were 84.4% and 86.5%. Treatment with 
aliskiren and aliskiren HCT was also associated 
with significant reductions from baseline 
to the end of study in msSBP and msDBP 
(Fig. 1). At week 26 (LOCF), mean reductions 
Table 3  Proportion of patients reaching the predened therapeutic blood pressure goal and the revised, classic therapeutic 
blood pressure goal at week 26 (LOCF)
Treatment erapeutic BP goala, n (%) “Classic” therapeutic BP goalb, n (%)
Aliskiren (n = 3,473)c 1,654 (49.5) 2,396 (71.7)
Aliskiren HCT (n = 1,353)c 643 (48.3) 1,035 (77.7)
All groups combined (n = 4,826)c 2,297 (49.2) 3,431 (73.4)
Full analysis set
BP blood pressure, DBP diastolic blood pressure, LOCF last observation carried forward, HCT hydrochlorothiazide, SBP 
systolic blood pressure
a SBP/DBP <140/90 mmHg (<130/80 mmHg for patients with diabetes)
b SBP/DBP <140/90 mmHg
c e total number of patients with post-baseline value is n = 3,341 for aliskiren, n = 1,332 for aliskiren HCT and n = 4,673 
for all groups combined
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in msSBP/msDBP were 24.1/12.2 mmHg for 
aliskiren and 27.6/14.1 mmHg for aliskiren HCT 
(P < 0.001 vs. baseline for both treatments). 
Changes in mean sitting BP were numerically 
greater with increasing severities of baseline 
BP (Fig. 2). Indeed, in those patients (n = 420) 
with severe hypertension (SBP of ≥180 mmHg), 
msSBP declined by 49.3 mmHg from baseline 
(P < 0.001). In general, high BP response rates 
(>86%) as well as consistent reductions in BP 
compared with baseline (Fig. 3) were observed 
in important subgroups such as patients with 
diabetes, the elderly (aged ≥65 years), obese 
patients (BMI ≥30 kg/m2) and those with 
isolated systolic hypertension (ISH) relative to 
the overall population. Furthermore, aliskiren 
and aliskiren HCT were associated with 
meaningful reductions in BP when prescribed 
either alone, or as add-on to existing therapy. 
At week 26, the msSBP/msDBP change from 
baseline was –23.9/–13.0 mmHg when aliskiren 
or aliskiren HCT were prescribed alone; the 
corresponding values when aliskiren or aliskiren 
HCT were prescribed as add-on therapies were 
–26.4/–12.5 mmHg.
Safety and Tolerability
AEs occurred in a total of 101 (2.1%) patients 
(Table 4). The most common AEs included 
headache, onset of diabetes mellitus, abdominal 
discomfort, and dizziness (Table 4). The most 
frequently reported AEs that were suspected to 
be related to the medication of interest included 
abdominal discomfort, dizziness, headache, 
myalgia, and rash. Four deaths were reported 
during the study; three in the aliskiren group 
















































Fig. 1  Mean (standard error) change from baseline to week 26 (last observation carried forward) in mean sitting systolic 
blood pressure and mean sitting diastolic blood pressure according to treatment group. Full analysis set. BP blood pressure, 
HCT hydrochlorothiazide, msDBP mean sitting diastolic blood pressure, msSBP mean sitting systolic blood pressure. 
*P < 0.001 for msSBP and msDBP versus baseline BP
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(0.1%). None of the deaths were considered 
to be related to the medication of interest; 
reasons for death included pneumonia, sepsis, 
cerebral infarction, and chronic renal failure. 
Few patients in the overall population reported 
SAEs (n = 13; 0.3%). The majority of SAEs 
were considered unrelated to the medication 
of interest with the exception of five events, 
which occurred in three patients (angioedema, 
hypersensitivity, rash, hyperkalemia, increased 
blood creatinine). Pneumonia was the most 
common SAE and occurred in three patients. 
In total, AEs or SAEs led to permanent 
discontinuation of the medication of interest 
in 16 patients. Hyperkalemia was observed in 
20 patients (0.8%), nine of whom were found 
to have potassium values of ≥6.0 mmol/L, while 
hypokalemia (potassium <3.5 mmol/L) was 
recorded in 27 patients (1.1%) over the course 
of the study. 
Investigator Assessment of Effectiveness, 
Tolerability, and Treatment Compliance
At the end of the study, investigators assessed 
the effectiveness and tolerability of aliskiren and 
aliskiren HCT, as well as patients’ compliance 
with treatment. Overall, effectiveness of 
treatment was rated as “very good” or “good” 
for 89.3% of all patients, while tolerability was 
assessed as “very good” or “good” for 93.7% 
of patients. Compliance with treatment was 
rated as “very good” or “good” for 92.5% of all 
patients. At the end of the study, treatment with 
aliskiren or aliskiren HCT was continued by 95% 
of all patients.















































Fig. 2  Mean (standard error) change from baseline to week 26 (last observation carried forward) in mean sitting systolic 
blood pressure and mean sitting diastolic blood pressure according to severity of hypertension for all groups combined. Full 
analysis set. BP blood pressure, msDBP mean sitting diastolic blood pressure, msSBP mean sitting systolic blood pressure. 
*P < 0.001 for msSBP and msDBP versus baseline BP
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DISCUSSION
In this real-life study, performed in routine 
clinical practice in patients from Asia and 
the Middle East, treatment with aliskiren or 
aliskiren HCT either as single or add-on therapy 
resulted in almost half of all patients (49.2%) 
with hypertension achieving the prespecified 
therapeutic BP goal of <140/90 mmHg 
(<130/80 mmHg in patients with concomitant 
diabetes). It is noteworthy that 2,005 patients 
(41.5%) in this study had comorbid diabetes 
mellitus, and when therapeutic BP goal 
data were analyzed by diabetic status, just 
16.3% of these patients were found to have 
achieved the more aggressive BP target of 
<130/80 mmHg, thus impacting the overall 
therapeutic BP goal. Indeed, when a classic 
BP target of <140/90 mmHg was applied to all 
patients, therapeutic BP goal rates increased 
to 73.4% in the overall patient population 
and 73.8% in patients with diabetes. One of 
the potential reasons for the low proportion 
of patients with hypertension and diabetes 
achieving BP <130/80 mmHg might be due to 
“therapeutic inertia” among treating physicians, 
i.e., the failure of physicians to continue to 
treat to target BP once the classic BP target 
had been achieved. Therapeutic inertia is a key 
reason for failure to achieve recommended BP 
goals [22] and is a common problem in clinical 
practice worldwide, including countries such as 
Baseline BP: 154.8 154.2 153.2 157.6 156.3 93.9 92.7 81.5 90.9 94.8
msSBP
















































Diabetes (n = 2,005)
ISH (n = 629)
Elderly (n = 572)
Obese (n = 1,480)
Fig. 3  Mean (standard error) change from baseline to week 26 (last observation carried forward)  in mean sitting 
systolic blood pressure and mean sitting diastolic blood pressure according to patient subgroup for all groups combined. 
Full analysis set. ISH dened as systolic blood pressure ≥140 mmHg and diastolic blood pressure <90 mmHg; 
elderly dened as age ≥65 years; obese dened as body mass index ≥30 kg/m2. BP blood pressure, ISH isolated systolic 
hypertension, msDBP mean sitting diastolic blood pressure, msSBP mean sitting systolic blood pressure. 
*P < 0.001 for msSBP and msDBP versus baseline BP for all subgroups
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Pakistan [23] and the United Arab Emirates [24] 
where under-diagnosis and under-treatment 
rates pose serious challenges. 
The question of optimal BP goals in different 
groups of patients with hypertension has long 
been a subject of intense debate. In particular, 
the lower BP thresholds for patients with 
complicated hypertension, e.g., diabetes or renal 
disease, have come under scrutiny in recent years 
as a result of studies such as Action to Control 
Cardiovascular Risk in Diabetes (ACCORD). 
This trial showed that there was no benefit to 
be gained in a high-risk patient population 
with diabetes from intensively lowering SBP 
to a goal of <120 mmHg, with no difference 
reported in the primary endpoint (a composite 
of fatal and nonfatal major CV events) between 
this group and those who received standard 
therapy to lower BP to <140 mmHg [25]. 
Furthermore, the reappraisal of the European 
hypertension guidelines proposes that the BP 
goal for all patients with hypertension is set 
to <140/90 mmHg regardless of comorbidities 
or level of CV risk [26]. The authors of this 
reappraisal argue that the traditionally 
recommended BP goal of <130/80 mmHg in 
hypertensive patients with comorbid diabetes 
is not thought to be supported by clinical trial 
outcome evidence, nor is it thought to be a 
realistic target [26]. Similarly, a panel assembled 
by the Kidney Disease Improving Global 
Outcomes (KDIGO) recently raised the BP target 
from <130/80 mmHg to <140/90 mmHg in 
patients with chronic kidney disease, including 
those with proteinuria, based on evidence from 
a number of large clinical trials [27–29].
The present study also showed that during 
the observation and treatment period of 
Table 4  Most frequently reported adverse events
Adverse event Aliskiren Aliskiren HCT Total 
  n = 3,473 n = 1,353 n = 4,826 
  n (%) n (%) n (%)
Any 73 (2.1) 28 (2.1) 101 (2.1)
Headache 7 (0.2) 1 (0.1) 8 (0.2)
Onset of diabetes mellitus 1 (0.0) 5 (0.4) 6 (0.1)
Abdominal discomfort 5 (0.1) 0 (0.0) 5 (0.1)
Dizziness 5 (0.1) 0 (0.0) 5 (0.1)
Diarrhea 3 (0.1) 1 (0.1) 4 (0.1)
Myalgia 4 (0.1) 0 (0.0) 4 (0.1)
Rash 4 (0.1) 0 (0.0) 4 (0.1)
Hypertension 1 (0.0) 3 (0.2) 4 (0.1)
Asthenia 3 (0.1) 0 (0.0) 3 (0.1)
Pneumonia 3 (0.1) 0 (0.0) 3 (0.1)
Weight increased 2 (0.1) 1 (0.1) 3 (0.1)
Hyperglycemia 0 (0.0) 3 (0.2) 3 (0.1)
Hyperuricemia 1 (0.0) 2 (0.1) 3 (0.1)
Cough 3 (0.1) 0 (0.0) 3 (0.1)
Hypotension 3 (0.1) 0 (0.0) 3 (0.1)
Full analysis set
HCT hydrochlorothiazide
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26 ± 8 weeks, both aliskiren and aliskiren HCT 
produced significant reductions from baseline in 
msSBP and msDBP (25.1 mmHg and 12.8 mmHg, 
respectively; both P < 0.001 vs. baseline). The 
magnitude of reduction in BP was dependent 
on the baseline value, such that in patients 
with severe hypertension (SBP of ≥180 mmHg), 
reductions of 49.3 mmHg and 17.4 mmHg in 
msSBP and msDBP, respectively, were recorded 
at the end of the study. Similar reductions in BP 
to the overall results were also reported for the 
various patient subgroups, including patients 
with diabetes or ISH, and those who were obese 
or aged ≥65 years. Moreover, BP responder rates 
were consistently achieved in more than 80% of 
all patients during the study.
In general, the results observed in this real-
world, multiethnic study appear to correspond 
broadly with the results seen in other randomized, 
controlled trials of aliskiren and/or aliskiren 
HCT in different patient populations with 
hypertension, including those with metabolic 
comorbidities, such as diabetes or obesity [30], 
and the elderly [17]. The results of the present 
study are also in line with those reported in 
a recent observational, multicenter, open-
label study conducted in 2,070 patients with 
hypertension (25.3% of whom were also diabetic) 
in a “real-world” setting in Belgium [18]. In this 
particular study, mean reductions in SBP/DBP 
at 180 days following treatment with aliskiren 
300 mg were 22.9 and 10.5 mmHg, respectively 
(P < 0.001 vs. baseline for both). BP control 
(defined as <140/90 mmHg or <130/80 mmHg in 
patients with diabetes) was achieved in 36.4% of 
patients, and this increased to 56.3% when the 
2009 European guidelines criteria were applied, 
i.e., 130–139/80–89 mmHg. Other observational 
trials, specifically the 3A registry of 14,988 
patients in Germany [20] and the Aliskiren 
Canadian Hypertension Registry (ANCHOR) of 
approximately 15,000 patients with hypertension 
with or without type 2 diabetes [19], should 
help to provide further important information 
regarding the use and effectiveness of aliskiren in 
real-life practice conditions.
As with many observational studies, the 
reported incidence of AEs was low (2.1%). 
Although the most frequently reported AEs 
were headache, onset of diabetes mellitus, 
abdominal discomfort, and dizziness, each 
event was reported in less than 0.2% of all 
patients. The four deaths that occurred during 
the observational period, as well as the majority 
of SAEs, were not considered to be study-drug 
related. Recognizing the inherent limitations 
with observational studies, aliskiren-based 
therapy appeared to be well tolerated in this 
hypertensive population, with a profile not 
dissimilar to what has been reported in other 
randomized, controlled trials [14, 17, 30].
We note the findings of the recently presented 
Aliskiren Trial In Type 2 Diabetes Using Cardio-
Renal Disease Endpoints (ALTITUDE) study, 
where no benefit of a dual RAAS regimen 
(including aliskiren) was observed, and a greater 
incidence of AEs was noted in patients with 
type 2 diabetes and renal impairment compared 
with standard of care over a median follow-up 
period of 32.9 months [31]. We conducted a 
posthoc subanalysis of the hypertensive patients 
with diabetes in the present study who had 
received a dual RAAS regimen; in the present 
study population the overall incidence of AEs 
was 1.3% (8/607) in the diabetic patients who 
received dual RAAS, compared with an incidence 
of 2.2% (93/4,219) in all other patients in the 
study. These data, of course, should be viewed 
in the context of the observational nature 
of the study, the different study population 
recruited, and the shorter treatment duration. 
Consequently, despite the benign safety data 
observed in the present study, we would still 
caution against the use of aliskiren in a diabetic 
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population as add-on to another RAAS inhibitor, 
in line with the updated prescribing information 
available from the study sponsor.
An additional element of the present study 
was the investigator assessment of treatment 
effectiveness, tolerability, and compliance. 
Overall, the effectiveness and tolerability of 
aliskiren and aliskiren HCT was rated as “good” or 
“very good” for almost all patients (effectiveness: 
89.3%; tolerability: 93.7%). Treatment 
compliance was also judged to be “good” or 
“very good” for more than 90% of patients; a 
reflection of the proportion of patients (95%) 
who continued on treatment after the study. 
Accepting that heightened compliance may 
partly be a consequence of patient involvement 
in a study, these findings are noteworthy 
nonetheless given that noncompliance with 
treatment is a major obstacle to achieving BP 
goal worldwide, including South and East Asia 
where challenges surrounding economic burden 
and access to treatment dominate [32, 33]. 
A potential limitation of this study is 
its nonrandomized, open-label, single-arm 
design, which may allow for selection bias or 
confounding variables, so potentially limiting 
the interpretation of results. However, this 
design was adopted to reflect the effectiveness, 
tolerability, and safety of aliskiren and aliskiren 
HCT in daily clinical practice. Furthermore, loss 
to follow-up is typically seen as a drawback of 
observational studies, although the present 
results indicated that only a small proportion 
of patients were lost to follow-up (3.8%). The 
subjective evaluation of the effectiveness, 
tolerability, and compliance with aliskiren and 
aliskiren HCT is also a limitation of this study. 
Nevertheless, the observational nature of this 
trial allowed for the collection of a substantial 
amount of data from a multiethnic, hypertensive 
patient population where aliskiren and aliskiren 
HCT were prescribed in a naturalistic setting.
CONCLUSIONS
Treatment with either aliskiren or aliskiren HCT 
alone or as add-on therapy was associated with 
statistically significant and clinically meaningful 
reductions in BP compared with baseline. Almost 
half of all patients achieved a therapeutic BP 
goal of <140/90 (and <130/80 mmHg in patients 
with diabetes) and this number increased to in 
excess of 70% when a therapeutic BP goal of 
<140/90 mmHg was applied to all patients. In 
this real-world, naturalistic setting, treatment 
based on aliskiren and aliskiren HCT proved 
to be effective and well-tolerated BP-lowering 
therapies in this multiethnic population with 
arterial hypertension.
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